Proof-of-Concept and Feasibility Study to Evaluate the Effect of β-Glucan on Protective Qi Deficiency in Adults

Mark Levy; Jun-rong WU; Jian-pin SHI; Hao-jie CHENG; Xuan-qiao QU; Ira Bernstein; Robert Sinnott; Jun-qiang TIAN

doi:10.1007/s11655-020-3430-y

Your Location：

Home >

Browse articles >

Proof-of-Concept and Feasibility Study to Evaluate the Effect of β-Glucan on Protective Qi Deficiency in Adults

Original Article | Updated：2021-09-01

- Proof-of-Concept and Feasibility Study to Evaluate the Effect of β-Glucan on Protective Qi Deficiency in Adults
- Chinese Journal of Integrative Medicine Vol. 27, Issue 9, Pages: 666-673(2021)
- Affiliations：
  
  1.Research and Development Department, USANA Health Science, Inc., Salt Lake City, UT (84121), USA
  2.Elegant and Olive Health Clinic, Markham, ON (L3R 5V6), Canada
  3.Department of Family and Community Medicine, Humber River Hospital, Toronto, ON (M1V 2W7), Canada
- Author bio：
  
  Dr. TIAN Jun-qiang, E-mail: Jeremy.tian@us.usana.com
- Funds：
- DOI：10.1007/s11655-020-3430-y
  CLC：
- Published：01 September 2021，
  
  Published Online：19 August 2020，
  
  Accepted：10 April 2020
Scan for full text
Mark Levy, Jun-rong WU, Jian-pin SHI, et al. Proof-of-Concept and Feasibility Study to Evaluate the Effect of β-Glucan on Protective Qi Deficiency in Adults. [J]. Chinese Journal of Integrative Medicine 27(9):666-673(2021)
DOI：

Mark Levy, Jun-rong WU, Jian-pin SHI, et al. Proof-of-Concept and Feasibility Study to Evaluate the Effect of β-Glucan on Protective Qi Deficiency in Adults. [J]. Chinese Journal of Integrative Medicine 27(9):666-673(2021) DOI： 10.1007/s11655-020-3430-y.

摘要

Abstract

Objective:

To preliminarily explore the potential effect of β-glucan on Chinese medicine (CM) concept protective qi deficiency (PQD)

and the methodology for future definitive studies.

Methods:

To have a standardized assessment of PQD

a list of 13 potentially PQD-relevant parameters were firstly created

each with defined quantitative or categorial scales. Using the data from 37 participants with (21 cases) or without (16 cases) PQD

multivariate logistic modeling was conducted to create a preliminary diagnostic PQD risk score. Subsequently

21 participants diagnosed with PQD were treated with β-glucan in a dose of 200 mg/day for 8 weeks. Data were collected for trial acceptability measures (rate of recruitment

withdrawal

and compliance)

and the participants were assessed for PQD status at baseline and every 2 weeks thereafter.

Results:

The preliminary logistic model consisted of 3 parameters (low voice and apathy

aversion to wind and cold

and Cun pulse). The resulting risk score demonstrated a degree of PQD-predicting accuracy that

as evaluated by statistical (discrimination and classification) methods

was higher than those obtained from any of the individual candidate parameters. The 21 PQD participants treated with β-glucan demonstrated good receptibility and a time-dependent improvement in PQD status as evidenced by the decrease of PQD participant to 9.5% at the end of study.

Conclusions:

This study demonstrated the effect of proof-of-concept of β-glucan on improving PQD and the proof-of-concept of a multivariate-model-derived diagnostic PQD risk score. It also indicated feasibility for future definitive studies. Studies like this embody an innovative approach that uses therapies derived from the mainstream biomedicine to enrich therapeutics guided by CM principle. (Trial registration No. NCT03829228)

关键词

Keywords

β-glucanprotective qi deficiencyChinese medicinediagnostic risk score

references

Chan G, Chan W, Sze D. The effects of β-glucan on human immune and cancer cells. J Hematol Oncol 2009;2:25.

Bashir KM, Choi J-S. Clinical and physiological perspectives of β-glucans: the past, present, and future. Int J Mol Sci 2017;18:1906.

China State Bureau of Quality and Technical Supervision. National standards of People's Republic of China-clinical terminology of TCM diagnosis and therapeutics-symptoms and syndromes. 1st ed. Beijing:Standard Press of China; 1997.

Altman DG, Royston P. The cost of dichotomising continuous variables. Br Med J 2006;332:1080.

Unschuld PU, transl. Huang Di Nei Jing Ling Shu. Oakland, California: University of California Press; 2016.

Chen JX, Xue FF. Origin and development of microcosmic syndrome differentiation. J Integr Med 2005;3:342-346.

Yao ML, ed. Pulse quantitative classification and pulse recording format. Sixteen lectures on clinical pulse science. 1st ed. Beijing:China Press of Traditional Chinese Medicine; 1983.

Liang MX, Hong ZP. A preliminary study on the method of quantifying symptoms of traditional Chinese medicine. Attached quantitative method of 30 syndromes of deficiency syndrome. China J Tradit Chin Med Pharm 1994;9:37-39.

Bergendiova K, Tibenska E, Majtan J. Pleuran (β-glucan from Pleurotus ostreatus) supplementation, cellular immune response and respiratory tract infections in athletes. Eur J Appl Physiol 2011;111:2033-2040.

Talbott S, Talbott J. Effect of beta 1, 3/1, 6 glucan on upper respiratory tract infection symptoms and mood state in marathon athletes. J Sport Sci Med 2009;8:509-515.

Talbott SM, Talbott JA. Baker's yeast beta-glucan supplement reduces upper respiratory symptoms and improves mood state in stressed women. J Am Coll Nutr 2012;31:295-300.

Babineau TJ, Hackford A, Kenler A, Bistrian B, Forse RA, Fairchild PG, et al. A phase Ⅱ multicenter, double-blind, randomized, placebocontrolled study of three dosages of an immunomodulator (PGGGlucan) in high-risk surgical patients. Arch Surg 1994;129:1204-1210.

Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974;19:716-723.

FIRTH D. Bias reduction of maximum likelihood estimates.Biometrika 1993;80:27-38.

Midi H, Sarkar SK, Rana S. Collinearity diagnostics of binary logistic regression model. J Interdiscip Math 2010;13:253:267.

Zweig MH, Campbell G. Receiver-operating characteristic (ROC)plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-577.

Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD):explanation and elaboration. Ann Intern Med 2015;162:W1-W73.

Lancaster GA, Thabane L. Guidelines for reporting non-randomised pilot and feasibility studies. Pilot Feasibil Stud 2019;5:114.

Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot feasibility Stud 2016;2:64.

Zhu F, Du B, Xu B. A critical review on production and industrial applications of beta-glucans. Food Hydrocoll 2016;52:275-288.

Azen R, Budescu DV. The dominance analysis approach for comparing predictors in multiple regression. Psychol Methods 2003;8:129-148.

Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988:411-413.

Bujang MA, Sa'at N, Sidik TMITAB. Determination of minimum sample size requirement for multiple linear regression and analysis of covariance based on experimental and non-experimental studies.Epidemiol Biostat Public Heal 2017;14:e12117-9.

Boh B, Berovic M, Zhang J, Zhi-Bin L. Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev 2007:265-301.

China Pharmacopeia Committe. China pharmacopeia. 1st ed. Beijing:China Medical Science and Technology Press; 2015.

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

β-Glucan Improves Protective Qi Status in Adults with Protective Qi Deficiency—A Randomized,Placebo-Controlled, and Double-Blinded Trial

Chemical Composition, Pharmacological Effects and Clinical Applications of Cinobufacini

Immunomodulatory Function of Pien Tze Huang in T Cell-Mediated Anti-tumor Activity against B16-F10, MC38 and Hep1-6 Tumor Models

Safflower Yellow Inhibits Progression of Hepatocellular Carcinoma by Modulating Immunological Tolerance via FAK Pathway

Immunoregulatory and Anti-cancer Activities of Combination Treatment of Novel Four-Herb Formula and Doxorubicin in 4T1-Breast Cancer Bearing Mice

Related Author

No data

Related Institution

Department of Family and Community Medicine, University of Toronto

Key Laboratory of Shaanxi Administration of Traditional Chinese Medicine for TCM Compatibility, Shaanxi University of Chinese Medicine

State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Faculty of Medicine and Life Science, Xiamen University

Fujian Pien Tze Huang Enterprise Key Laboratory of Natural Medicine Research and Development

Department of General Surgery, First People's Hospital of Hangzhou Lin'an District

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰